Table 1.
Summary of applications of MSC in targeted therapy of GC.
| Mechanism of action | Source of MSC | Anti-tumor compound | Effects | References |
|---|---|---|---|---|
| MSC as anti-tumor drug vectors | BM-MSC | Immunoapoptotin e23sFv-Fdt-tBid | Tumor growth↓ | (76) |
| BM-MSC | NK4: antagonist of hepatocyte growth factor receptors (Met) | Tumor necrosis↑; microvessel formation↓ |
(77) | |
| UCB-MSC | LIGHT(TNFSF14):TNF receptor | Tumor apoptosis↑ | (78) | |
| BM-MSC | Hemoglobin genes (HBA2 and HBB) | Chemotherapeutic effect↑ | (79) | |
| Target the MSC recruitment | BM-MSC | AMD3100: inhibitor of CXCL12/CXCR4 signaling axis | Tumor growth↓; gastric dysplasia↓ |
(80) |
| BM-MSC | SB225002: CXCR2 inhibitor | Tumor necrosis↑; growth↓; lymph node metastasis↓ |
(26) | |
| Target the MSC-GC interactions | GC-MSC | Resveratrol | EMT↓; metastasis↓ | (81) |
| BM-MSC | Anti-IL-6 antibody Anti-IL-8 antibody Anti-CCL-5 antibody 17β- estradiol |
Tumor invasiveness↓ | (82–84) | |
| BM-MSC | Etomoxir (ETX): inhibitor of FAO | Cancer stemness↓; chemo-resistance↓ |
(35) | |
| GC-MSC | YAP shRNA | Tumor migration↓; invasion↓; pro-angiogenic ability↓ |
(41) | |
| GC-MSC | PDGF-DD siRNA or su16f | Tumor proliferation↓;migration↓ | (42) | |
| GC-MSC | Curcumin | Tumor angiogenesis↓ | (64) |